## Carola H Ries

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3284150/publications.pdf

Version: 2024-02-01

26 papers 3,721 citations

331670 21 h-index 26 g-index

28 all docs 28 docs citations

28 times ranked

7141 citing authors

#	Article	IF	CITATIONS
1	Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. Cancer Cell, 2014, 25, 846-859.	16.8	1,033
2	Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy., 2017, 5, 53.		688
3	T cell–induced CSF1 promotes melanoma resistance to PD1 blockade. Science Translational Medicine, 2018, 10, .	12.4	229
4	Suppression of microRNA activity amplifies IFN- $\hat{l}^3$ -induced macrophage activation and promotes anti-tumour immunity. Nature Cell Biology, 2016, 18, 790-802.	10.3	214
5	In Vitro Generation of Monocyte-Derived Macrophages under Serum-Free Conditions Improves Their Tumor Promoting Functions. PLoS ONE, 2012, 7, e42656.	2.5	193
6	Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. Journal of Experimental Medicine, 2018, 215, 859-876.	8.5	150
7	T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. Cancer Cell, 2016, 30, 377-390.	16.8	141
8	Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell–Mediated Cytotoxicity Against Hepatocellular Carcinoma. Hepatology, 2019, 70, 1280-1297.	7.3	126
9	Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response. Nature Cell Biology, 2019, 21, 511-521.	10.3	121
10	Molecular Profiling and Functional Analysis of Macrophage-Derived Tumor Extracellular Vesicles. Cell Reports, 2019, 27, 3062-3080.e11.	6.4	118
11	CSF-1/CSF-1R targeting agents in clinical development for cancer therapy. Current Opinion in Pharmacology, 2015, 23, 45-51.	3 <b>.</b> 5	107
12	Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression. Cell Reports, 2016, 14, 1748-1760.	6.4	90
13	Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 541-551.	7.1	66
14	Macrophage Susceptibility to Emactuzumab (RG7155) Treatment. Molecular Cancer Therapeutics, 2016, 15, 3077-3086.	4.1	57
15	CD163 <sup>+</sup> tumorâ€associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes. Clinical and Translational Immunology, 2020, 9, e1108.	3.8	47
16	Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models. Science Translational Medicine, 2021, 13, .	12.4	44
17	Chemotherapy Combines Effectively with Anti–PD-L1 Treatment and Can Augment Antitumor Responses. Journal of Immunology, 2018, 201, 2273-2286.	0.8	38
18	Periostin Limits Tumor Response to VEGFA Inhibition. Cell Reports, 2018, 22, 2530-2540.	6.4	33

#	Article	IF	CITATION
19	A drug development perspective on targeting tumorâ€associated myeloid cells. FEBS Journal, 2018, 285, 763-776.	4.7	31
20	Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour. European Journal of Cancer, 2020, 141, 162-170.	2.8	29
21	Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma. Cancers, 2021, 13, 2400.	3.7	28
22	Targeting tumor-associated macrophages in cancer therapy and understanding their complexity. Oncolmmunology, 2014, 3, e955356.	4.6	27
23	Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition. Science Translational Medicine, 2021, 13, .	12.4	24
24	CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner. Cancer Immunology Research, 2020, 8, 1180-1192.	3.4	19
25	Tumor-associated macrophages promote intratumoral conversion of conventional CD4 <sup>+</sup> T cells into regulatory T cells via PD-1 signalling. Oncolmmunology, 2022, 11, 2063225.	4.6	14
26	Effects of IL-10 and Th 2 cytokines on human Mφ phenotype and response to CSF1R inhibitor. Journal of Leukocyte Biology, 2018, 103, 545-558.	3.3	6